Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 15;129(24):3971-3977.
doi: 10.1002/cncr.34983. Epub 2023 Aug 10.

A PI3K gene expression signature predicts for recurrence in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy

Nikhil T Sebastian  1 , Amy Webb  2 , Konstantin Shilo  3 , Ryan Robb  4 , Meng Xu-Welliver  5 , Karl Haglund  6 , Jeremy Brownstein  6 , Gina M DeNicola  7 , Changxian Shen  8 , Terence M Williams  8
Affiliations
Free article

A PI3K gene expression signature predicts for recurrence in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy

Nikhil T Sebastian et al. Cancer. .
Free article

Abstract

Introduction: Increasingly, early-stage non-small cell lung cancer (NSCLC) is treated with stereotactic body radiation therapy (SBRT). Although treatment is generally effective, a small subset of tumors will recur because of radioresistance. Preclinical studies suggested PI3K-AKT-mTOR activation mediates radioresistance. This study sought to validate this finding in tumor samples from patients who underwent SBRT for NSCLC.

Methods: Patients with T1-3N0 NSCLC treated with SBRT at our institution were included. Total RNA of formalin-fixed paraffin-embedded tumor biopsy specimens (pretherapy) was isolated and analyzed using the Clariom D assay. Risk scores from a PI3K activity signature and four published NSCLC signatures were generated and dichotomized by the median. Kaplan-Meier curves and Cox regressions were used to analyze their association with recurrence and overall survival (OS). The PI3K signature was also tested in a data set of resected NSCLC for additional validation.

Results: A total of 92 patients were included, with a median follow-up of 18.3 months for living patients. There was no association of any of the four published gene expression signatures with recurrence or OS. However, high PI3K risk score was associated with higher local recurrence (hazard ratio [HR], 11.72; 95% CI, 1.40-98.0; p = .023) and worse disease-free survival (DFS) (HR, 3.98; 95% CI, 1.57-10.09; p = .0035), but not OS (p = .49), regional recurrence (p = .15), or distant recurrence (p = .85). In the resected NSCLC data set (n = 361), high PI3K risk score was associated with decreased OS (log-rank p = .013) but not DFS (p = 0.54).

Conclusions: This study validates that higher PI3K activity, measured by gene expression, is associated with local recurrence and worse DFS in early-stage NSCLC patients treated with SBRT. This may be useful in prognostication and/or tailoring treatment, and merits further validation.

Keywords: PI3K; gene expression; non-small cell lung cancer; stereotactic body radiation therapy.

PubMed Disclaimer

References

REFERENCES

    1. Flores R, Patel P, Alpert N, Pyenson B, Taioli E. Association of stage shift and population mortality among patients with non-small cell lung cancer. JAMA Netw Open. 2021;4(12):e2137508. doi:10.1001/jamanetworkopen.2021.37508
    1. McMurry TL, Shah PM, Samson P, Robinson CG, Kozower BD. Treatment of stage I non-small cell lung cancer: what's trending? J Thorac Cardiovasc Surg. 2017;154(3):1080-1087. doi:10.1016/j.jtcvs.2017.03.122
    1. Syed YA, Stokes W, Rupji M, et al. Surgical outcomes for early stage non-small cell lung cancer at facilities with stereotactic body radiation therapy programs. Chest. 2022;161(2):833-844. doi:10.1016/j.ijrobp.2021.10.179
    1. Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol. 2010;94:1-11. doi:10.1016/j.radonc.2009.12.008
    1. Chang JY, Mehran RJ, Feng L, et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021;22(10):1448-1457. doi:10.1016/s1470-2045(21)00401-0

Publication types

MeSH terms

Substances

LinkOut - more resources